Allopurinol in combination with thiopurine induces mucosal healing and improves clinical and metabolic outcomes in IBD
Open Access
- 11 October 2017
- journal article
- research article
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 10 (11) , 819-827
Abstract
Thiopurines, azathioprine (AZA) and 6-mercaptopurine (6-MP) are common maintenance medications for inflammatory bowel disease (IBD). Excessive methylation via thiopurine methyltransferase (TPMT) frequently causes therapeutic failure. Allopurinol reduces excessive 6-methyl-mercaptopurine (6-MMP) while enhancing 6-thioguanine (6-TGN) levels. The aim of this study was to evaluate clinical, metabolic and endoscopic impact of allopurinol in combination with low-dose thiopurine in IBD. Retrospective review of consecutive cases treated with allopurinol. Metabolites and their ratios (6-MMP/6-TGN) were compared pre- and post-allopurinol. Clinical and endoscopic remission were assessed. Allopurinol (n = 66) reduced mean dose of AZA by 70% (p < 0.01). Baseline levels (SD) 6-TGN, 6-MMP and 6-MMP/6-TGN were 165 (64), 9388 (5234) and 59.8 (30.3), respectively. These values improved on allopurinol to 297 (102), 896 (1031) and 3.4 (4.0), respectively (p < 0.0001). Therapeutic 6-TGN level (>235) was achieved in 49/58 cases on allopurinol combination therapy, versus 9/58 monotherapy (p = 0.0001). Among the thiopurine failure group (40 patients), clinical remission or response was observed in 65% and 22% of patients, respectively. In the asymptomatic group with excessive 6-MMP, 11/14 achieved sustained remission on allopurinol. Repeat colonoscopy (n = 28) showed mostly endoscopic remission (67.9%) or improvement (17.8%). Few had unimproved lesions (14.3%). Importantly, 46% of cases had complete mucosal healing. Two patients had cancer on combination therapy (de novo pancreatic cancer and fatal recurrence of metastatic testicular cancer). Elevated transaminases were reduced on allopurinol (48.2 versus 6.9%) (p < 0.001); no change in leukopenic or infectious events occurred. Allopurinol in combination with low-dose thiopurine corrected excessive 6-MMP levels, resulting in clinical remission and mucosal healing in the majority of cases. The potential cancer risk of allopurinol and thiopurine combination therapy needs further research.Keywords
This publication has 40 references indexed in Scilit:
- A Systematic Review of Factors That Contribute to Hepatosplenic T-Cell Lymphoma in Patients With Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2011
- Infliximab, Azathioprine, or Combination Therapy for Crohn's DiseaseNew England Journal of Medicine, 2010
- Correlation Between the Crohn's Disease Activity and Harvey–Bradshaw Indices in Assessing Crohn's Disease SeverityClinical Gastroenterology and Hepatology, 2010
- Incidence of Neoplasms in Patients Who Develop Sustained Leukopenia During or After Treatment With 6-Mercaptopurine for Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2006
- Thiopurine TherapiesTherapeutic Drug Monitoring, 2005
- Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurineAlimentary Pharmacology & Therapeutics, 2005
- Toxicity of low dose azathioprine and 6-mercaptopurine in rat hepatocytes. Roles of xanthine oxidase and mitochondrial injuryJournal of Hepatology, 2004
- 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity.Gut, 1996
- Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid TherapyNew England Journal of Medicine, 1994
- Low-dose allopurinol plus azathioprine/ cyclosporin/prednisolone, a novel immunosuppressive regimenThe Lancet, 1993